Jeffrey Bonacorda - 18 Mar 2026 Form 3 Insider Report for KAZIA THERAPEUTICS LTD (KZIA)

Role
VP, Finance and Controller
Signature
/s/ Jeffrey Bonacorda
Issuer symbol
KZIA
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 17:55:11 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bonacorda Jeffrey VP, Finance and Controller THREE INTERNATIONAL TOWERS, LEVEL 24, 300 BARANGAROO AVE, SYDNEY, NSW, AUSTRALIA /s/ Jeffrey Bonacorda 18 Mar 2026 0002115111

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KZIA American Depositary Share Option (Right to Buy) 18 Mar 2026 American Depositary Shares 5,000 $0.2300 Direct F1, F2
holding KZIA American Depositary Share Option (Right to Buy) 18 Mar 2026 American Depositary Shares 100,000 $6.58 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in four equal annual installments beginning on June 24, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on June 24, 2024.
F2 Each ADS option is convertible into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
F3 The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.

Remarks:

Exhibit 24 - Power of Attorney